|
CALYPSO: A three-arm randomized phase II study of durvalumab alone or with savolitinib or tremelimumab in previously treated advanced clear cell renal cancer. |
|
|
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen |
Research Funding - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Johnson & Johnson; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen |
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; MSD; Pfizer; Roche |
|
|
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Ipsen; Roche |
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; EUSA Pharma; Ipsen; Janssen-Cilag; Novartis; Pfizer; Roche; Sanofi |
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Janssen-Cilag; Pfizer; Roche |
|
|
Honoraria - Astellas Oncology; AstraZeneca Spain; Bayer; Bristol-Myers Squibb; Janssen; MSD; Pfizer; Roche |
Consulting or Advisory Role - Astellas Oncology; Bayer; BMSi; Clovis Oncology; Ipsen; Janssen; MSD; Pfizer; Roche |
Research Funding - MSD (Inst); Pfizer; Takeda (Inst) |
Travel, Accommodations, Expenses - Astellas Oncology; Bayer; BMSi; Clovis Oncology; Ipsen; Janssen; Novartis |
|
|
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Ipsen; Novartis; Pierre Fabre |
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen-Cilag |
|
|
Travel, Accommodations, Expenses - Pfizer/EMD Serono |
|
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Enara Bio; GlaxoSmithKline; Immatics; Ixaka; Janssen; Pfizer (Inst); T-Knife; Zelluna |
Research Funding - 3-V Biosciences (Inst); Abbvie (Inst); Actuate Therapeutics (Inst); Adaptimmune (Inst); Adaptimmune (Inst); Agalimmune (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); BerGenBio (Inst); Blueprint Medicines (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Carrick Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); GenMab (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Immutep (Inst); Incyte (Inst); Janssen (Inst); kinex (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Millenium Pharamceuticals (Inst); MSD (Inst); Novartis (Inst); Octimet (Inst); Orion (Inst); Pfizer (Inst); Redx Pharma (Inst); Roche (Inst); Roche (Inst); Sierra Oncology (Inst); Synthon (Inst); Takeda (Inst); Tarveda Therapeutics (Inst) |
Travel, Accommodations, Expenses - Ixaka |
Other Relationship - iMatch |
|
|
Speakers' Bureau - Britol Myers Squibb (Inst) |
Research Funding - Scancell (Inst) |
Travel, Accommodations, Expenses - EUSA Pharma |
|
|
Honoraria - Bayer; Bristol-Myers Squibb; Eisai Europe; Novartis; Pfizer |
Consulting or Advisory Role - Ipsen; Pfizer |
Research Funding - Janssen Oncology (Inst) |
Travel, Accommodations, Expenses - Ipsen; Novartis; Pfizer; Roche |
|
Gopalakrishnan Srinivasan |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Agence Unik; Bristol-Myers Squibb; Cambridge Healthcare research; Eisai; Incyte; Merck Serono; Novartis; Pfizer; RCGP; Royal College of Physicians; touchEXPERTS; touchIME; VJOncology |
Consulting or Advisory Role - Agence Unik; Apple Tree Partners; Aptitude Health; AstraZeneca; Bristol-Myers Squibb; Calithera Biosciences; Debiopharm Group; eCancer; Eisai; EUSA Pharma; GlaxoSmithKline; Goldman Sachs; Incyte; Insel Gruppe; iOnctura; Ipsen; Merck Serono; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche; Seagen; Ultimovacs |
Research Funding - Achilles Therapeutics (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Immunocore (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - GlaxoSmithKline; Pierre Fabre; Roche/Genentech |
|
|
Honoraria - Bristol-Myers Squibb; Eisai; Novartis; Pfizer |
Consulting or Advisory Role - Bristol-Myers Squibb |
Research Funding - Eisai (Inst); Merck (Inst); Roche (Inst); Viralytics (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; GlaxoSmithKline; Ipsen; Janssen; Roche |
|
|
Consulting or Advisory Role - Bicycle Therapeutics (Inst); Boxer Capital (Inst); Bristol-Myers Squibb (Inst); Duke Street Bio (Inst); Eisai (Inst); Ellipses Pharma (Inst); EUSA Pharma (Inst); MedAnnex (Inst); MSD (Inst); Pfizer/EMD Serono (Inst); Vaccitech (Inst) |
Speakers' Bureau - Bristol-Myers Squibb (Inst); EUSA Pharma (Inst); Ipsen (Inst) |
Research Funding - BiolineRx (Inst); BioNTech (Inst); Boston Pharmaceuticals (Inst); Incyte (Inst); Merck Sharp & Dohme (Inst); Nouscom (Inst); Nucana (Inst); Roche/Genentech (Inst); Sapience Therapeutics (Inst); Sierra Oncology (Inst); Verastem (Inst) |
Travel, Accommodations, Expenses - BioNTech; Bristol-Myers Squibb; Ipsen; MSD |
|
|
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Janssen-Cilag; MSD Oncology; Pfizer; Roche; Sanofi |
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Janssen-Cilag; Merck Sharp & Dohme; Pfizer; Roche; Sanofi |
Research Funding - Astellas Pharma; Pfizer; Roche (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen-Cilag; MSD Oncology; Pfizer; Roche |
|
|
Employment - AstraZeneca/MedImmune |
|
|
Employment - AstraZeneca/MedImmune |
|
|
No Relationships to Disclose |
|
|
Research Funding - AstraZeneca (Inst); Merck (Inst); Roche/Genentech (Inst) |
|
|
No Relationships to Disclose |